Skip to main content
OpenTrials

Clinical trial condition

Relapsing Multiple Sclerosis

Explore clinical trials studying Relapsing Multiple Sclerosis. Study availability and eligibility vary by location and protocol.

69 public trials 9 recruiting studies
Refine in advanced search Browse all conditions

Relapsing Multiple Sclerosis trial results

Active, not recruiting

Effects of Ocrevus in Relapsing Multiple Sclerosis

NCT04387734

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Georgia State University Atlanta, Georgia, United States
  • Multiple Sclerosis Center of Atlanta Atlanta, Georgia, United States
View Trial Details
Active, not recruiting

Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

NCT06847724

Conditions
Relapsing Multiple Sclerosis
Locations
  • Sandoz Investigational Site Maitland, Florida, United States
  • Sandoz Investigational Site Ormond Beach, Florida, United States
  • Sandoz Investigational Site Banja Luka, Bosnia and Herzegovina
  • Sandoz Investigational Site Bihać, Bosnia and Herzegovina
View all 41 locations
View Trial Details
Active, not recruiting

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

NCT03650114

Conditions
Relapsing Multiple Sclerosis
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • North Central Neurology Associates PC Cullman, Alabama, United States
  • Barrow Neurological Clinics at St Josephs Hospital and MC Phoenix, Arizona, United States
  • Fullerton Neuro and Headache Ctr Fullerton, California, United States
View all 295 locations
View Trial Details
Active, not recruiting

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

NCT06564311

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • North Central Neurology Cullman, Alabama, United States
  • Center for Neurology and Spine Phoenix, Arizona, United States
  • Perseverance Research Center Scottsdale, Arizona, United States
  • Regina Berkovich MD PhD, Inc West Hollywood, California, United States
View all 47 locations
View Trial Details
Active, not recruiting

A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis

NCT06396039

Conditions
Relapsing Multiple Sclerosis
Locations
  • Local Institution - 0002 Beijing, Beijing Municipality, China
  • Local Institution - 0012 Guangzhou, Guangdong, China
  • Local Institution - 0022 Guangzhou, Guangdong, China
  • Local Institution - 0008 Shenzhen, Guangdong, China
View all 25 locations
View Trial Details
Completed

A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

NCT05232825

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Chronic Disease, +11 more
Locations
  • Neurology Associates PA Maitland, Florida, United States
  • University of South Florida Tampa, Florida, United States
  • Johns Hopkins Hospital Baltimore, Maryland, United States
  • Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis Owosso, Michigan, United States
View all 37 locations
View Trial Details
Completed

Characterizing the Use of Ofatumumab in a Real World Setting

NCT05090033

Conditions
Relapsing Multiple Sclerosis
Locations
  • Novartis Investigative Site Concord, New South Wales, Australia
  • Novartis Investigative Site Southport, Queensland, Australia
  • Novartis Investigative Site Clayton, Victoria, Australia
  • Novartis Investigative Site Melbourne, Victoria, Australia
View Trial Details
Completed

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

NCT04353492

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Fullerton Neuro and Headache Ctr Fullerton, California, United States
  • CU Anschutz Med Campus Aurora, Colorado, United States
  • Christiana Care Health Services Newark, Delaware, United States
  • Memorial Healthcare System Hollywood, Florida, United States
View all 123 locations
View Trial Details

Related conditions